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Abstract 
Background: Proteasome inhibitors are attractive cancer therapeutic agents because they can regulate apoptosis-
related proteins. Bortezomib also known as Velcade®, a proteasome inhibitor that has been approved by the food and 
drug administration for treatment of patients with multiple myeloma, and many clinical trials are ongoing to examine 
to the efficacy of bortezomib for the treatment of other malignancies. Bortezomib has been shown to induce apop-
tosis and inhibit cell growth of many cancer cells. In current study, we determine whether bortezomib induces cell 
death/apoptosis in CML.
Methods: Cell viability was measured using MTT assays. Apoptosis was measured by annexin V/PI dual staining and 
DNA fragmentation assays. Immunoblotting was performed to examine the expression of proteins. Colony assays 
were performed using methylcellulose.
Results: Treatment of CML cells with bortezomib results in downregulation of S-phase kinase protein 2 (SKP2) and 
concomitant stabilization of the expression of p27Kip1. Furthermore, knockdown of SKP2 with small interference RNA 
specific for SKP2 caused accumulation of p27Kip1. CML cells exposed to bortezomib leads to conformational changes 
in Bax protein, resulting in loss of mitochondrial membrane potential and leakage of cytochrome c to the cytosol. 
In the cytosol, cytochrome c causes sequential activation of caspase-9, caspase-3, PARP cleavage and apoptosis. 
Pretreatment of CML cells with a universal inhibitor of caspases, z-VAD-fmk, prevents bortezomib-mediated apoptosis. 
Our data also demonstrated that bortezomib treatment of CML downregulates the expression of inhibitor of apop-
tosis proteins. Finally, inhibition of proteasome pathways by bortezomib suppresses colony formation ability of CML 
cells.
Conclusions: Altogether, these findings suggest that bortezomib suppresses the cell proliferation via induction of 
apoptosis in CML cells by downregulation of SKP2 with concomitant accumulation of p27Kip1, suggesting that  
proteasomal pathway may form novel therapeutic targets for better management of CML.
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Background
Ubiquitin proteasome system (UPS), a multi-catalytic 
protein complex, plays critical roles in the regulation of 
key signaling proteins involved in many cellular functions 
[1–4]. Dysregulation of ubiquitin-dependent pathways 
has been implicated in the pathogenesis of many cancers 
[5–7]. SKP2, an SCF ubiquitin ligase belonging to the fam-
ily of F-box proteins has been shown to be involved in 
cell cycle progression and cell proliferation [8–10]. It has 
been shown that SKP2 is overexpressed in many cancers 
[11–14]. SKP2 plays a rate-limiting factor in SCF protein 
complex that degrades p27Kip1 via ubiquitination and 
subsequently proteasome-mediated degradation [8–10]. 
Overexpression of SKP2 has been linked with poor prog-
nosis of many cancers [15–18]. The significance of SKP2 
in regulating p27Kip1 expression has been shown in 
various human malignancies, including diffuse large cell 
lymphoma and many solid tumors [19–23]. SKP2 gene 
silencing using small inference RNA (siRNA) in many 
cancer cell lines has led to the accumulation of p27Kip1, 
p21waf1 expression and inhibited cell growth and survival 
via cell cycle arrest and induction of apoptosis [8–10]. 
The anticancer agents induce cytotoxic effects mainly 
by inducing apoptotic cell death in various cancer cells. 
Growing number of studies have shown that proteasome 
inhibitors suppress the growth of many human cancer cells 
via induction of apoptosis mediated cell cycle arrest/cell 
death [24–27]. The bortezomib, a proteasome inhibitor 
has been approved for the treatment of multiple myeloma 
and mantle cell lymphoma in the United States by the US. 
Food and drug administration and for those patients who 
had already gone through one prior chemotherapeutic 
treatment. Several clinical studies are currently ongoing to 
determine the efficiency of bortezomib for the better man-
agement of other types of human cancers [28].
In the present study, our findings indicate that borte-
zomib-mediated inhibition of cell proliferation of chronic 
myelogenous leukemia cells (CML) cell lines is associated 
with down-regulation of SKP2 with concomitant up-reg-
ulation/stabilization of p27Kip1. Furthermore, CML cells 
treated with this particular proteasome inhibitor; bort-
ezomib showed inhibition of cell growth, and induction 
of apoptosis by activation of the caspase cascade and dis-
ruption of the mitochondrial equilibrium. Altogether our 
findings suggest that bortezomib mediated downregula-
tion of SKP2 is a novel effect in CML cells and implicates 
that proteasome inhibitors may have a novel therapeutic 
potential for the intervention of CML.
Methods
Reagents and antibodies
Bortezomib (Velcade®) and antibodies against Bax, tubu-
lin, cytochrome c, GAPDH, caspase-3, caspase-9, and 
PARP were purchased from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA). Antibodies against BID and 
cleaved caspase-3 were purchased from Cell Signaling 
Technologies (Beverly, MA, USA). XIAP, cIAP1, and cas-
pase-8 antibodies were purchased from R and D (USA). 
BD Cytofix/Cytoperm plus fixation and permeabiliza-
tion solution kit with BD GolgiPlug, propidium iodide 
(PI) staining solution, annexin V binding buffer, mito-
chondrial membrane potential detection (JC-1) kit, stain 
buffer (FBS), annexin V-FITC antibody, H2AX (pS139)-
Alexa Fluor 647 antibody, rabbit anti-active caspase-3- 
Bv605 antibody and PARP cleaved form-AF700 antibody 
were obtained from BD Biosciences (NJ, USA). Apoptotic 
DNA-ladder kit was obtained from Roche (Penzberg, 
Germany).
Cell culture
K562, AR230, and LAMA-84 CML cells were grown in 
RPMI 1640 medium supplemented with 10 % (v/v) fetal 
bovine serum, 100 U/ml penicillin and 100 U/ml strepto-
mycin at 37 °C in humidified atmosphere containing 5 % 
CO2.
3‑(4, 5‑Dimethylthiazol‑2‑yl)‑2, 5‑diphenyltetrazolium 
bromide assays
1  ×  104 cells were treated with the indicated doses of 
bortezomib in a final volume of 0.1 ml for 24 h. The abil-
ity of bortezomib to suppress cell growth was determined 
by MTT cell proliferation assays, as previously described 
[29]. Replicates of three wells for each dosage including 
vehicle control were analyzed for each experiment.
Cell cycle analysis
To determine whether bortezomib can induce cell 
cycle arrest in CML cells, K562, and AR230 cells were 
exposed to various doses of bortezomib for 24 h. Cells 
were washed, fixed with 70 % ethanol, and incubated for 
30 min at 37 °C with 0.1 % RNase A in phosphate-buffer 
saline (PBS). Cells were washed again, resuspended, and 
stained with 25  μg/ml propidium iodide (PI) for 30 in 
PBS min at room temperature. Cell distribution across 
the cell cycle was analyzed by flow cytometry using BD 
LSRFortessa analyzer (BD Biosciences) as described pre-
viously [30].
Annexin V/propidium iodide dual staining
K562 and AR230 cells were incubated with the indicated 
concentrations of bortezomib. The cells were collected 
by centrifugation, washed with PBS and stained with 
fluorescein-conjugated annexin V and propidium iodide 
(BD Biosciences) and the percentage of cells undergoing 
apoptosis was measured by flow cytometry as previously 
described [31].
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Knock down study using SKP2 siRNA
SKP2 siRNA and scrambled control siRNA were obtained 
from Qiagen. K562 and AR230 cells were transfected 
using Lipofectamine 2000 reagent (Invitrogen) according 
to the manufacturer’s instructions. Six hours post-trans-
fection, the lipid and siRNA complex were removed, and 
fresh RPMI medium with serum was added. After 48  h 
of incubation, cells were lysed and immunoblotted with 
antibodies against SKP2, p27Kip1, and GAPDH as a load-
ing control.
Cell lysis and immunoblotting
CML cells were treated with bortezomib for various 
time periods as described in the figure legends and lysed 
as described previously [32]. Proteins (25–50  µg) were 
resolved by SDS-PAGE and transferred to polyvinylidene 
difluoride (PVDF) membrane (Immobilon, Millipore, 
Billerica, MA). Immunoblotting was performed using 
various antibodies, the blots were developed and further 
visualized under a ChemiDoc system (Amersham, Bio-
Rad, USA).
Quantitation of DNA double strand breaks (H2AX)
K562 cells were treated with various doses of bortezomib 
for 24 h. After the incubation period, the cells were fixed 
and permeabilized using BD Cytofix/Cytoperm plus fixa-
tion and permeabilization solution kit, as per protocol 
from the manufacturer. Approximately 0.3  ×  106 cells 
in FBS were stained with 5.0 µl of H2AX (pS139)-Alexa 
Fluor 647 antibody for 30 min at room temperature. The 
cells were washed once with FBS (300  g for 5  min) and 
then resuspended in FBS. The DNA breaks were meas-
ured by flow cytometry using BD LSRFortessa analyzer.
DAPI staining
105 cells of K562 CML cell line were incubated in the 
presence of different concentrations of bortezomib (10, 
25 and 50 nm) in a final volume of 1 ml per condition for 
24 h. The cells were then counted using hemacytometer 
in duplicates and 6 × 104 cells were washed with 1 × PBS, 
centrifuged at 1200  rpm for 5  min. The pellet then was 
resuspended in 150ul of 1× PBS and using the Cytofun-
nels set we did cytospining of the samples on the micro-
scopic slides at 800 rpm for 5 min. Furthermore, the cells 
were fixed with 100  % methanol for 30  min at −20  °C 
followed by permeabilization for 5 min at 4  °C in 0.2 % 
Triton X-100 solution in PBS. Cells were then washed 
and nuclei were counterstained with 1  µg/ml DAPI in 
PBST for 5 min and rinsed 3 times in PBST and once in 
H2O to remove salts. Slides were then mounted using 
Vectashield antifade mounting medium (Vector Labora-
tories, CA, USA) and covered with cover glasses. Excess 
of fluid was removed with paper towel and slides were 
sealed with transparent histofluid and kept overnight at 
4 °C. Imaging was performed the next day on Zeiss axio 
imager microscope using 63×/1.25 oil objectives.
Mitochondrial membrane potential measurement
K562 cells were treated with bortezomib for 24 h, briefly 
stained with JC-1 stain for 15 min in dark at 37 °C as per 
instructions from the kit manufacturer. The cells were 
washed with 1× assay buffer, re-suspended using 500 µl 
of the same buffer. After that mitochondrial membrane 
potential was measured by flow cytometry using a BD 
LSRFortessa analyzer (BD Biosciences, USA) [33].
Flow cytometric analysis of active caspase‑3 and cleaved 
PARP
K562 cells were treated with various doses of borte-
zomib for 24 h, cells were fixed and permeabilized using 
BD Cytofix/Cytoperm plus fixation and permeabiliza-
tion solution kit, as per protocol from the manufacturer. 
Approximately 0.3 ×  106 cells in FBS were stained with 
5.0  µl each of anti- Active Caspase-3-BV605 and PARP 
Cleaved Form-AF700 antibodies for 30  min at room 
temperature. Cells were then washed with FBS and then 
resuspended using the same buffer. Quantification of the 
active caspase-3 and cleaved PARP in the cells were ana-
lyzed by flow cytometry using BD LSRFortessa analyzer.
Measurement of cytochrome c release
To measure the release of cytochrome c from mitochon-
dria, we performed the assay as reported earlier [34]. 
K562 cells were treated with 10, 25 and 50  nm borte-
zomib for 24 h, cells were harvested and resuspended in 
hypotonic buffer (1 mM Tris–HCl, pH 7.4, 0.13 M NaCl, 
5 mM KCl, 7.5 mM MgCl2). Cells were homogenized and 
centrifuged to obtain the cytosolic as well as mitochon-
drial fractions. Twenty to twenty-five microgram of pro-
tein from cytosolic and mitochondrial fractions of each 
sample were analyzed by immunoblotting using an anti-
cytochrome c and tubulin antibody.
Clonogenic leukemic assays using methylcellulose
K562, AR230 and LAMA84 (1 × 104) cells were treated 
with and without bortezomib as described in the figure 
legends and mixed with 1.0  mL of MethoCult H4034 
Optimum (Stem Cell Technologies). Colonies were 
counted based on morphology after 10 days.
Statistical analysis
Comparisons between groups were made using the 
paired Student’s t test. The software GraphPad Prism 
(version 5.0 for Windows, GraphPad Software Inc., 
San Diego, CA, http://www.graphpad.com). Values of 
* p < 0.05 were considered statistically significant.
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Results
Bortezomib is antiproliferative and induces apoptosis 
in CML cells
To assess the effect of bortezomib on cell viability, a 
panel of human CML cell lines (AR230, LAMA-84, and 
K562) were treated with increasing concentrations (10, 
25 and 50 nm) of bortezomib for 24 h. A dose-depend-
ent decrease in cell proliferation was observed in all the 
treated cell lines (Fig.  1a). Bortezomib-mediated inhibi-
tion of cell viability was also observed in a time-depend-
ent manner (data not shown).
To investigate whether the inhibition of cell viability 
induced by bortezomib is due to cell cycle arrest or apop-
tosis K562 and AR230 cells were treated with different 
doses of bortezomib for 24  h as indicated. An increase 
in subG0 population was observed in a dose-dependent 
manner with the cell lines, K562, and AR230 (Fig.  1b). 
The sub-G0 population of cells was found to increase 
from 6.48  % in control cells to 19.5, 33.8 and 49.8  % at 
10, 25 and 50 nm bortezomib-treated K562 cells respec-
tively. Similar results were obtained in AR230 cells with 
an increase of sub-G0 population from 6.56 % in control 
cells to 16.2, 27.6 and 38.4 % in cells treated with 10, 25 
and 50  nm of bortezomib respectively. The increase in 
sub-G0 population was accompanied by decreased G0/
G1 and G2/M phases in bortezomib-treated CML cells.
To investigate whether the increased sub-G0 popula-
tion in response to bortezomib treatment in CML cells 
was a resultant of induction of apoptosis, K562, and 
AR230 cells were treated with 10, 25 and 50  nm borte-
zomib for 24 h and apoptosis was measured by annexin-
V-FITC/PI dual staining. As shown in Fig. 1c, Additional 
file  1: Figure S1a, b, treatment of CML cells with bort-
ezomib resulted in a dose-dependent increase in apop-
tosis. Furthermore bortezomib treatment resulted in an 
increase in early (annexin +ive and PI −ive cells) and late 
(annexin +ive and PI +ive cells) stage apoptotic cell frac-
tions in K562 and AR230 respectively. There was signifi-
cant bortezomib-mediated apoptosis in K562 cell (18  % 
at 10 nm, p < 0.05; 40.1 % at 25 nm, p < 0.001, 81.1 % at 
50 nm, p < 0.001) and in AR230 cells (13.5 % at 10 nm, 
p < 0.001; 33.2 % at 25 nm, p < 0.001, 38.4 % at 50 nm, 
p  <  0.001) with respect to the untreated control cells. 
Bortezomib treatment was found to be more effective 
towards K562 cells line when compared to AR230 cells 
with all tested doses (Additional file 1: Figure S1c, d). To 
further confirm the bortezomib-mediated apoptosis in 
K562 and AR230 cells, we performed the DNA fragmen-
tation analysis as described in the “Methods” section. An 
increase in DNA fragmentation was observed upon bort-
ezomib treatment of both cell lines in a dose-dependent 
manner (Fig. 1d). These results correlated with the quan-
tification of phospho-γ-H2AX (S139) by flow cytometry 
as shown in Additional file  2: Figure S2a. Bortezomib 
treatment causes a significant increase in DNA double 
strand breaks as evident by increase in phosphorylation 
of H2AX. DNA damage leads to double-stranded breaks 
that are always followed by the phosphorylation of the 
histone H2A variant, H2AX. Since phosphorylation of 
H2AX at Serine 139 is abundant, fast, and directly corre-
lates well with each double-stranded break, it is used as a 
sensitive marker for DNA damage [35]. Furthermore, we 
performed DAPI immunofluorescence staining to visu-
alize apoptotic nuclear bodies—a common hallmark of 
apoptosis. As shown in Additional file 2: Figure 2b, bort-
ezomib treatment of K562 cells causes a dose-dependent 
malformation of nuclei architecture followed by subse-
quent formation of apoptotic bodies. The results suggest 
that the antiproliferative activity of bortezomib in CML 
cells is via induction of apoptosis.
Bortezomib inhibits proteasome activity via SKP2 
downregulation in CML cells
During growth and division, the cell requires a periodic 
activation of a family of protein kinases known as several 
cyclin-dependent kinases (CDK), whose expression levels 
are highly regulated by ubiquitination and proteasomal 
degradation [36–39]. Several studies have reported that 
the expression of p27Kip1, a CDK inhibitor, is dysregu-
lated by proteasome pathway [40–42]. The F-box protein, 
SKP2 is an ubiquitin ligase that plays a vital role in the 
degradation of p27Kip1 [15, 19, 20]. In accordance with 
these facts, we intend to check whether bortezomib-
mediated apoptosis is due to proteasome inhibition and 
degradation of SKP2. The proteasome inhibition in K562 
and AR230 cells mediated by bortezomib treatment after 
24 h was evidenced by the accumulation of polyubiquit-
inated proteins (Fig. 2a).
Moreover, it was observed that bortezomib treatment 
resulted in downregulation of SKP2 in both cell lines, 
with a concomitant up-regulation of p27Kip1 (Fig.  2b). 
Similar results were obtained using another CML cell 
line, LAMA-84 (Additional file 3: Figure S3). This antago-
nistic effect observed for SKP2 and p27Kip1 suggests that 
bortezomib induced- downregulation of SKP2 forms an 
important mechanism to induce apoptosis in CML cell 
lines via up-regulation of p27Kip1. Since the p27Kip1 
abundance increased as a result of bortezomib treatment 
of CML cells, we investigated the effect of bortezomib on 
the stability of p27Kip1 using cycloheximide chase assay. 
As indicated in Fig. 2c, bortezomib treatment increased 
the stability of p27Kip1 in K562 cells. These findings sug-
gest that bortezomib-mediated p27Kip1 up-regulation is 
a result of p27Kip1 stabilization.
To further confirm the antagonistic effect observed 
for SKP2 and p27Kip1, we sought to silence the SKP2 
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expression in K562 cells by specific siRNA against SKP2. 
We observed that the knockdown of SKP2 resulted in the 
increased expression of p27Kip1 in CML cells (Fig.  2d). 
Altogether, the results suggest that the bortezomib-
induced apoptosis is mediated by the downregulation of 
SKP2 and concomitant accumulation of p27Kip1 in CML 
cells.
Bortezomib‑induced apoptosis: involvement 
of mitochondrial pathway and activation of caspases
Activation of caspase-8 followed by truncation of Bid 
leads its translocate to the mitochondrial membrane 
which results in activation of the intrinsic apoptotic 
pathway. In accordance to that, we sought to deter-
mine, whether bortezomib-induced apoptosis involves 
the mitochondrial-mediated activation of caspases. Our 
data suggest that K562 cells treated with bortezomib for 
24  h showed activation of caspase-8 (Fig.  3a), followed 
by the truncation of Bid, which led to the conformational 
change of Bax protein as shown by the increase in acti-
vated form of Bax (6A7) in Fig. 3b, c.
The altered conformation of Bax protein has been 
shown to reduce the mitochondrial membrane poten-
tial (MMP), leading to matrix remodeling resulting in 
Fig. 1 Effects of Bortezomib on proliferation, cell cycle progression, and apoptosis in CML cells. a Bortezomib inhibits the cell viability of CML cells. 
AR230, LAMA-84 and K562 cells were incubated with 10, 25, 50 and 100 nm bortezomib for 24 h. Cell proliferation assays were performed using 
MTT as described in “Methods” section. The graph displays the mean ± SD (standard deviation) of three independent experiments with replicates of 
six wells for all the doses. **p < 0.01, ***p < 0.001 b Bortezomib induces the increase of subG0 population of CML cells. K562 and AR230 cells were 
treated with 10, 25 and 50 nm of bortezomib for 24 h. Thereafter, the cells were washed, fixed and stained with propidium iodide, and analyzed for 
DNA content by flow cytometry as described in “Methods” section. c Bortezomib induces apoptosis in CML cells. K562 and AR230 cells were treated 
with 10, 25 and 50 nm of bortezomib for 24 h and cells were subsequently stained with flourescein-conjugated annexin-V and propidium iodide (PI) 
and analyzed by flow cytometry. d Bortezomib treatment of CML cells induces DNA fragmentation. K562 and AR230 cells were treated with 10, 25 
and 50 nm bortezomib as indicated for 24 h and DNA was extracted and separated by electrophoresis on 1.5 % agarose gel
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cytochrome c release. We, therefore, investigated whether 
the bortezomib has an effect on the MMP in K562 cells. 
Cells were treated with increasing concentration of bort-
ezomib and labeled using JC1 dye and MMP was meas-
ured by flow cytometry. JC-1 is a lipophilic, cationic dye 
that can specially enter into mitochondria. In control cells 
with elevated mitochondrial membrane potential, the 
dye forms J-aggregate complex with intense red fluores-
cence, while in apoptotic cells with reduced MMP, it gives 
a green fluorescence. Figure 3d illustrates a dose-depend-
ent loss of MMPs (p < 0.001 in at all doses) in CML cells 
as indicated by the increase in JC1 green fluorescence—a 
marker of apoptotic cells. Similar results were obtained by 
using Rhodamine 6G, another dye utilized for the detec-
tion of mitochondrial membrane potential (data not 
shown). We then investigated the release of cytochrome c 
from the mitochondria in bortezomib-treated cells. As is 
evident in Fig. 3e cytochrome c was found to be released 
into the cytosol after bortezomib treatment. There was a 
concomitant decrease in cytochrome c level in the mito-
chondrial fraction of K562 cells. The results indicate that 
bortezomib-mediated inhibition of proteasome pathways 
Fig. 2 Downregulation of SKP2 pathway by proteasome inhibition causes accumulation of ubiquitinated proteins and upregulates the expression 
of p27Kip1. a Bortezomib-mediated ubiquitination of various proteins in CML cells. AR230 and K562 cells were treated with different doses of bort-
ezomib for 24 h as indicated. After cell lysis, equal amounts of proteins were separated by SDS–PAGE, transferred to PVDF membrane, and immuno-
blotted with antibodies of anti-ubiquitin and GAPDH as indicated b Bortezomib treatment down-regulated the expression of SKP2 and increased 
the level of p27Kip1. AR230 and K562 cells were treated with various doses of bortezomib for 24 h as indicated. After cell lysis, equal amounts of 
proteins were separated by SDS-PAGE, transferred to PVDF membrane, and immuno-blotted with antibodies against SKP2, p27Kip1 and GAPDH as 
indicated. c Bortezomib treatment of K562 cells causes the stabilization of p27. K562 cells were treated with and without 25 nm of Bortezomib for 
24 h. Cells were then treated with 10 μM Cyclohexamide for 30, 60, 120 and 240 min. Cells were lysed and equal amounts of proteins were sepa-
rated by SDS-PAGE, transferred to PVDF membrane, and immuno-blotted with antibodies against p27Kip1 and GAPDH as indicated. Each band was 
quantified by densitometry and ratio of p27/GAPDH was plotted. d SKP2 siRNA expression downregulates SKP2 and accumulated p27Kip1. AR230 
and K562 cells were transfected with Scrambled siRNA (100 nm) and SKP2 siRNA (50–100 nm) using Lipofectamine 2000 as described in “Methods” 
section. After 48 h of transfection, cells were lysed and equal amounts of proteins were separated by SDS-PAGE, transferred to PVDF membrane, and 
immunoblotted with antibodies against SKP2, P27Kip1, and GAPDH as indicated
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led to the depolarization of MMP, which in turn led to the 
increased flux of cytochrome c in the cytosol. We further 
investigated whether the bortezomib-mediated release of 
cytochrome c can activate caspase-9, subsequently cas-
pase-3 and eventually PARP cleavage. Figure 4a shows that 
bortezomib treatment of K562 and AR320 cells resulted 
in the activation of caspase-9, caspase-3, and cleavage of 
PARP. Similar results were obtained with LAMA-84 cells 
(Additional file  4: Figure S4). Furthermore, activation of 
caspase-3 and PARP cleavage was determined by flow 
cytometry. The data was in accordance with Western 
blot analysis showing significant caspase-3 activation and 
PARP cleavage in bortezomib-treated CML cells (Fig. 4b). 
In addition, pre-treatment of K562 cells with z-VAD-
FMK, a generalized inhibitor of caspases, prevented bort-
ezomib-mediated activation of caspase-3 and apoptosis 
(Fig. 4c), suggesting the involvement of caspases in borte-
zomib-mediated apoptosis.
Fig. 3 Bortezomib-induced activation of caspase-8 and mitochondrial apoptotic pathway. Bortezomib-induced activation of caspase-8 a and BID b 
in CML cells. K562 cells were treated with 10, 25, and 50 nm bortezomib for 24 h. Cells were lysed and 25 μg of protein were separated by SDS-PAGE, 
transferred to PVDF membrane, and immuno-blotted with antibodies against caspase-8, BID, and GAPDH. c Bortezomib-induced Bax conforma-
tion change in CML cells. After treating with 10, 25, and 50 nm bortezomib for 24 h, K562 cells were lysed in 1 % Chaps lysis buffer and subjected 
to immunoprecipitation with anti-Bax (6A7) antibody for detection of conformational changed Bax protein. In addition, the total cell lysates were 
applied directly to SDS-PAGE, transferred to PVDF membrane and immuno-blotted with anti-Bax polyclonal antibody (lower blot). d Bortezomib 
treatment causes the loss of mitochondrial membrane potential in CML cells. K562 cells were treated with 10, 25 and 50 nm of bortezomib for 
24 h. Live cells with intact mitochondrial membrane potential (red bar) and dead cells with lost mitochondrial membrane potential (green bar) 
were measured by JC1 staining and analyzed by flow cytometry as described in “Methods” section. ***p < 0.001. e Bortezomib-induced release 
of cytochrome c. K562 cells were treated with 10, 25 and 50 nm of bortezomib for 24 h. Cytoplasmic and mitochondrial fractions were isolated as 
described in “Methods” section. Cell extracts were separated on SDS-PAGE, transferred to PVDF membrane, and immunoblotted with an antibody 
against cytochrome c and tubulin
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Inhibitors of apoptosis proteins (IAP) have been 
shown to have direct effects on caspases [43]. There-
fore, we investigated whether bortezomib-induced cell 
death involved modulation of IAP members which 
determines the cell’s response to the apoptotic signal. 
Therefore, we sought to determine whether bortezomib 
has any effect on the expression of IAP members such 
as XIAP and CIAP-1. As shown in Fig. 4d, bortezomib 
treatment resulted in down-regulation of XIAP cIAP-1 
and survivin. These findings suggest that bortezomib-
mediated apoptosis involved these IAP proteins in 
CML cells.
Anti‑leukemic effects of bortezomib in CML cell lines
To assess the anti-leukemic effects induced by borte-
zomib treatment in a more patho-physiologically relevant 
Fig. 4 Activation of caspase-9, caspase-3, and cleavage of PARP induced by bortezomib treatment in CML cells. a Bortezomib mediated activa-
tion of caspase cascade in CML cells. AR230 and K562 cells were treated with and without 10, 25 and 50 nm of bortezomib for 24 h. Cells were 
lysed and 25 μg of proteins were separated on SDS-PAGE, transferred to PVDF membrane, and immunoblotted with antibodies against caspase-9, 
caspase-3, cleaved caspase-3, PARP and GAPDH. b Bortezomib-induced activation of caspase-3 and PARP cleavage in K562 cells was determined by 
flow cytometry as described in “Methods” section. *p < 0.05, ***p < 0.001. c Effect of z-VAD-fmk on bortezomib-induced apoptosis and activation of 
caspase-3. K562 cells were pre-treated with 80 μM z-VAD/fmk for 2 h and subsequently treated with 25 nm for 24 h. Cells were divided in two parts. 
In one part apoptotic cells were measured with fluorescein-conjugated annexin-V and propidium iodide (PI) and analyzed by flow cytometry (upper 
panel). The other part of the cells were lysed and 20 μg protein were separated by SDS-PAGE, transferred to PVDF membrane, and immunoblotted 
with antibodies against caspase-9, pro-caspase-3, cleaved caspase-3, and GAPDH (lower panel). d Bortezomib down-regulates expression of XIAP in 
CML cells. K562 and AR230 cells were treated with 10, 25 and 50 nm bortezomib for 24 h. Following incubation, cells were harvested and proteins 
were isolated separated on SDS-PAGE and immunoblotted with antibodies against XIAP, cIAP1, Survivin and GAPDH as indicated (representative of 
several experiments)
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approach, we evaluated the effects on leukemic progeni-
tors (CFU-L) using clonogenic assays in methylcellulose. 
Treatment of K562 and AR230 cells with bortezomib 
resulted in greater inhibition of CFU-L colony growth 
of leukemic precursors in both cell lines. The effect was 
dose-dependent, and a significant decrease was observed 
at 10 nm treatment with of bortezomib (Fig. 5).
Discussion
Many of the recent studies have reported the essential 
role that SKP2 play in the degradation of p27Kip1 in 
association with various cancers [15, 44]. Degradation of 
p27Kip1, a mammalian cyclin-dependent kinase inhibi-
tor, is an essential step for the necessary transition from 
quiescence to the proliferative state. The ubiquitination 
Fig. 5 Antileukemic effects of bortezomib on CML cells. a K562 and b AR230 cells were plated on methyl-cellulose with 1, 5 and 10 nm of bort-
ezomib for 10 days. Cells were counted manually under the microscope. The bar graphs represent the percentage of myeloid colonies. The graph 
represents the mean of the two independent experiments *p < 0.05
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of p27Kip1 enabled by SKP2 protein leads to its rapid 
proteasome-mediated degradation [8]. A substantial 
number of studies account for the interaction between 
these two proteins whereby it was testified that the 
expression of SKP2 was inversely linked with p27Kip1 
levels [12, 14]. Taking this into account, in the current 
study, we sought to investigate the relationship between 
SKP2 and p27Kip1 in the pathogenesis of CML. The 
protein p27KIP1 is a primary target of SKP2 in context 
to cell growth and survival. It has been shown that SKP2 
knockout mouse embryonic fibroblasts (MEFs) grow sig-
nificantly slower than wild-type mouse MEFs suggest-
ing an important role of SKP2 in cell proliferation [45]. 
It is further reported that MEFs devoid of SKP2 have 
an amplified expression of p27Kip1, which provides the 
genetic evidence that SKP2 function leads to the degra-
dation of p27Kip1 tumor suppressor protein. Further-
more, in various human cancers the increased expression 
of SKP2 and reduced levels of p27Kip1 have been linked 
to poor prognosis [46].
It is worth elucidating that SKP2 down-regulation lead-
ing to the p27KIp1 accumulation represents an impor-
tant underlying mechanism for the antiproliferative effect 
of the large anticancer compounds, including bortezomib 
[15, 19, 47] and imatinib [48]. Our findings thus add bort-
ezomib to the growing list of anticancer compounds that 
target the SKP2–p27KIP1 axis to inhibit the growth and 
survival of many cancers [14, 47, 49].
Proteasome inhibitors were reported to stabilize 
many of the cellular proteins, primarily inducing cell 
cycle arrest followed by programmed cell death. It was 
observed from the current study that the treatment of 
CML cells with bortezomib induced a dose-dependent 
inhibition of cell viability via induction of apoptosis. 
Bortezomib-mediated reduction of SKP2 led the up-
regulation of p27Kip1—a known target of proteasome 
[15, 19, 47]. Cycloheximide chase experiment strongly 
suggested that bortezomib stabilizes the expression of 
p27kip1. Furthermore, silencing of SKP2 expression by 
siRNA resulted in increased levels of p27Kip1, strongly 
suggesting a potential role of bortezomib-mediated 
apoptosis in CML cell lines.
The mechanism of bortezomib-mediated apoptosis in 
CML cells is still not known. Recent studies have impli-
cated that, the down-regulation of SKP2 by cell adhesion 
to stroma cells, leads to up-regulation of p27Kip1 [50]. 
It could be inferred from these studies that regulation of 
SKP2 happens at both translational and post-translational 
levels. In our present study, we speculate that borte-
zomib-induced down-regulation of SKP2 follows a similar 
mechanism; however, further investigations in this direc-
tion is needed. Apoptosis involves a number of anti- and 
pro-apoptotic signaling proteins in its execution [51]. In 
the current study inhibition of ubiquitin–proteasomal 
pathway by bortezomib in CML cells leads to induction 
of apoptosis via caspase-8 activation followed by trunca-
tion of Bid that resulted in a conformational change in the 
proapoptotic protein, Bax. Bax protein has been shown 
to affect the integrity of mitochondrial membrane lead-
ing to the loss of its potential resulting in the release of 
cytochrome c into the cytosol. Bortezomib-induced loss 
of mitochondrial membrane potential helps to achieve the 
release of cytochrome c from the cristae regions to the 
cytosol. The cytochrome c release leads to the formation 
of apoptosome by interaction with apaf1 and caspase-9, 
which in turn is resulting in sequential activation of cas-
pase-3 and PARP [52]. Furthermore, it was observed that 
bortezomib treatment in CML cell lines led to reduced 
expression of inhibitory apoptotic proteins such as XIAP, 
cIAP1, and survivin implicating the role of IAPs in the 
activation of caspase-9 and caspase-3 in bortezomib-
induced apoptosis. The data suggest that inhibition of 
ubiquitin–proteasome pathway in CML cells induces 
apoptosis via caspase cascade activation.
Altogether, the results from our current study estab-
lish that SKP2 ubiquitin–proteasome plays a pivotal role 
in the growth and survival of CML cells. Bortezomib-
mediated down-regulation of SKP2 expression leads to 
the accumulation and stabilization of p27Kip1, thereby 
inducing apoptosis in CML cells through the release of 
cytochrome c from the mitochondria and activation of 
downstream caspase cascades. We anticipate that our 
present work showing bortezomib mediated downregu-
lation of SKP2 as a result of its correlation with p27Kip1 
stabilization and inhibition of CML cell proliferation is 
a novel finding that can have potential implications for 
future pre-clinical and clinical studies in CML. The pre-
cise mechanism of bortezomib mediated downregulation 
of SKP2 is not known. Recently SKP2 has been shown to 
be downregulated by cell adhesion to stroma cells lead-
ing upregulation p27kip1 [50]. These studies further 
suggested that regulation of SKP2 occurs at both trans-
lational and posttranslational levels. We speculate that 
bortezomib-induced downregulation of SKP2 follows 
similar mechanisms, however it needs further investiga-
tions. Indeed, it can open up new avenues of investiga-
tions aimed at determining the efficacy of an innovative 
approach for targeted therapy of the CML subset show-
ing alteration in the ubiquitin–proteasome system with 
inhibitors of proteasome pathways.
Conclusions
In conclusion, our results show that bortezomib-medi-
ated inhibition of cell proliferation of CML cell lines is 
associated with down-regulation of SKP2 with concomi-
tant up-regulation/stabilization of p27Kip1. Furthermore, 
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CML cells treated with bortezomib exhibited inhibi-
tion of cell growth and induced apoptosis by activation 
of the caspase cascade as well as the disruption of the 
mitochondrial equilibrium. Altogether our findings sug-
gest that bortezomib-mediated anti-proliferative effect 
of CML cells is novel, which implies that this proteasome 
inhibitor is of high therapeutic potential that might be 
used in the strategic intervention of CML.
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Additional file 1: Figure S1. Bortezomib-mediated induction of early 
(Annexin +ive and PI −ive cells), late apoptosis (Annexin +ive and PI 
+ive cells) and necrosis fractions (Annexin −ive and PI +ive cells) in 
K562 (A) and AR230 (B) cells. Cells were treated with 10, 25 and 50 nM of 
bortezomib for 24 h and cells were subsequently stained with flourescein-
conjugated annexin-V and propidium iodide (PI) and analyzed by flow 
cytometry. The graph displays the mean ± SD (standard deviation) of 
three independent experiments for all the doses. *** p < 0.001. Bort-
ezomib mediated induction apoptosis in K562 (C) and AR230 (D) cells. The 
percentage of apoptotic cells relative to control population is shown. The 
graph displays the mean ± SD (standard deviation) of three independent 
experiments for all the doses.
Additional file 2: Figure S2. Bortezomib treatment induces double-
stranded breaks in K562 cells (A). Cells were treated with 10, 25 and 50 nM 
of bortezomib for 24 h and cells were subsequently stained with H2AX 
(pS139)-Alexa Fluor 647 antibody as described in “Methods” section and 
then analyzed by flow cytometry. The graph displays the mean ± SD 
(standard deviation) of three independent experiments for all the doses. 
*** p < 0.001. (B) Shown are images from fluorescence microscope of 
Bortezomib tretaed K562 cells stained with DAPI. K562 cells were treated 
with 10, 25 and 50 nm of bortezomib for 24 h and nuclei were subse-
quently stained with 4’,6-diamidino-2-phenylindole (DAPI) and examined 
by fluorescence microscopy. Imaging was performed the next day on 
Zeiss axio imager microscope using 63 × /1.25 oil objectives.
Additional file 3: Figure S3. Bortezomib treatment down-regulated the 
expression of SKP2 and increased the level of p27Kip1. LAMA-84 cells were 
treated with various doses of bortezomib for 24 h as indicated. After cell 
lysis, equal amounts of proteins were separated by SDS-PAGE, transfered 
to PVDF membrane, and immuno-blotted with antibodies against SKP2, 
p27Kip1 and GAPDH as indicated.
Additional file 4: Figure S4. Bortezomib mediated activation of 
caspase-3 and PARP cascade in LAMA-84 cells. AR230 and K562 cells were 
treated with and without 10, 25 and 50 nm of bortezomib for 24 h. Cells 
were lysed and 25 μg of proteins were separated on SDS-PAGE, transferred 
to PVDF membrane, and immunoblotted with antibodies against cas-
pase-3, PARP and GAPDH.
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